Cervical cancer caused by the infection with the human papillomavirus (HPV) remains the fourth leading killer of women worldwide. Therefore, more efficacious treatments are needed. We are developing radioimmunotherapy (RIT) of HPV-positive cervical cancers by targeting E6 and E7 viral oncoproteins expressed by the cancer cells with the radiolabeled monoclonal antibodies (mAbs). To investigate t...

UNLABELLED Tumor targeting and therapeutic efficacy of (177)Lu-labeled monoclonal antibody (mAb) RS7 (antiepithelial glycoprotein-1) was evaluated in a human nonsmall cell lung carcinoma xenograft model. The potential of (177)Lu-labeled RS7 was compared with that of RS7 labeled with (90)Y and a residualizing form of (131)I. METHODS A 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid...

BACKGROUND Peptide receptor radionuclide therapy (PRRT), employed for treatment of neuroendocrine tumors (NETs) is based on over-expression of Somatostatin Receptors (SSTRs) on NETs. It is, however, limited by high uptake and retention of radiolabeled peptide in kidneys resulting in unnecessary radiation exposure thus causing nephrotoxicity. Employing a nanocarrier to deliver PRRT drugs specifi...

We think of this as saying that under some mild conditions on our probability space, the distribution of the linear form Q is roughly the same, regardless of the actual underlying distribution. There are, of course, a family of different central limit theorems, with different “mildness conditions” leading to different notions of the closeness of the resulting distributions. As “central limit th...

Two major phyla are responsible for human disease: Nemathelminthes (roundworms) and Platyhelminthes (flatworms). Nematodes are categorized by their migration route. Enterobius and Trichuris are found intraintestinally, whereas filarial worms live in tissue and lymphatics. Platyhelminthes is further divided into two classes: cestodes, or tapeworms; and trematodes, or flukes. Nemathelminthes (Rou...

Introduction: Bone pain palliation therapy is a mandate in handling end-stage cancer patients. The development of new ligands with higher stability, better pharmacokinetics and lower unwanted tissue uptakes (liver and GI) is still ongoing. Methods: In this work Lu-177 labeled (3-amino-1-hydroxypropane-1,1-di-yl)-bis-(phosphonate) (177Lu-pamidronate; 177Lu-PAM ), ...

INTRODUCTION. . . . . . . . ............ 168 Material and methods.. . ............ 168 Results of experiments.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 169 DISCUSSION. .. ................... ................................... 174 SWMARY ....................................................................... 177 LITERATFR...

AIM The goal of the present study was to test the (177)Lu-labelled anti-PSMA monoclonal antibody 3/F11 ((177)Lu-DOTA-3/F11) as a new radioimmunotherapeutic agent in a prostate cancer SCID mouse xenograft model. MATERIALS AND METHODS The mAb 3/F11 was (177)Lu labelled using 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) as chelating agent. DOTA-3/F11 was tested for cell bindin...